FAROTTI, LUCIA
 Distribuzione geografica
Continente #
NA - Nord America 644
EU - Europa 337
AS - Asia 157
Totale 1.138
Nazione #
US - Stati Uniti d'America 644
IE - Irlanda 140
VN - Vietnam 75
IT - Italia 73
HK - Hong Kong 46
CN - Cina 30
RO - Romania 23
RU - Federazione Russa 23
UA - Ucraina 14
FI - Finlandia 12
FR - Francia 12
DE - Germania 10
SE - Svezia 9
BE - Belgio 5
GB - Regno Unito 5
PL - Polonia 3
SG - Singapore 3
CH - Svizzera 2
CZ - Repubblica Ceca 2
NL - Olanda 2
TR - Turchia 2
JP - Giappone 1
LU - Lussemburgo 1
RS - Serbia 1
Totale 1.138
Città #
Chandler 210
Dublin 140
Dong Ket 75
San Mateo 51
Hong Kong 46
Altamura 37
Wilmington 32
Medford 29
Princeton 28
Des Moines 27
Lawrence 27
Perugia 23
Ann Arbor 22
Timisoara 18
Beijing 17
Andover 14
Falls Church 10
Los Angeles 10
Saint Petersburg 10
Norwalk 7
Brussels 5
Bucharest 5
San Paolo di Civitate 5
Helsinki 4
Redwood City 4
Den Haag 2
Fairfield 2
Fremont 2
Izmir 2
Lappeenranta 2
New York 2
Paris 2
Singapore 2
Boardman 1
Bologna 1
Denver 1
Edinburgh 1
Falkenstein 1
Houston 1
Kiev 1
Ludwigshafen 1
Luxembourg 1
Moscow 1
Nis 1
Queens 1
Radeberg 1
Redmond 1
Rome 1
San Severo 1
Totale 888
Nome #
The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease 74
Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI) 70
Diagnostic performance of a fully automated chemiluminescent enzyme immunoassay for Alzheimer's disease diagnosis 62
Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology 61
Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study 57
Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms 51
Unraveling Pathophysiological Mechanisms of Parkinson’s Disease: Contribution of CSF Biomarkers 47
Biomarker-based signature of alzheimer’s disease in pre-MCI individuals 47
Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study 46
Differential diagnosis between Alzheimer's disease and other dementias: Role of cerebrospinal fluid biomarkers 43
Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases 43
Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes 41
Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine 40
Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker 38
Two-year longitudinal monitoring of amnestic mild cognitive impairment patients with prodromal Alzheimer's disease using topographical biomarkers derived from functional magnetic resonance imaging and electroencephalographic activity 38
Parkinson's and Lewy body dementia CSF biomarkers 37
Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: A 'European ADNI study' 35
Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study 35
Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms 35
Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study 34
Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders 34
White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers 34
Late-Onset Epilepsy With Unknown Etiology: A Pilot Study on Neuropsychological Profile, Cerebrospinal Fluid Biomarkers, and Quantitative EEG Characteristics 34
Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson’s disease 32
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry 32
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. 30
Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study 29
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores 24
null 13
Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores 8
Totale 1.204
Categoria #
all - tutte 5.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.049


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20192 0 0 0 0 0 0 0 0 0 0 2 0
2019/202050 1 0 0 0 0 1 11 3 11 10 13 0
2020/2021186 2 1 7 6 64 2 5 4 1 4 2 88
2021/2022223 4 38 0 2 11 8 7 58 8 17 35 35
2022/2023596 33 110 7 71 40 75 0 30 202 2 19 7
2023/2024126 14 21 9 7 2 0 42 3 4 15 9 0
Totale 1.204